The kinase PLK1 promotes Hedgehog signaling–dependent resistance to the antiandrogen enzalutamide in metastatic prostate cancer
Science Signaling · 18.03.2025 · 18 (878)
DOI: 10.1126/scisignal.adi5174 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Signaling, erschienen am 18.03.2025. Verfasst von Qiongsi Zhang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, KY 40536, USA. Hauptthemen laut MEDLINE: Phenylthiohydantoin, Drug Resistance, Neoplasm, Signal Transduction, Hedgehog Proteins. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Enzalutamide, a second-generation androgen receptor inhibitor (also known as an antiandrogen), is used to treat patients with metastatic castration-resistant prostate cancer (CRPC). Tumors often acquire resistance to enzalutamide. Tumor progression and enzalutamide resistance are associated with decreased abundance of the tumor suppressor PDCD4. In normal dividing cells, PDCD4 abundance is low when that of the kinase PLK1 is high. In this study, we found that PLK1 acted on PDCD4 to promote enzalutamide resistance in CRPC cells in culture and in mice via a mechanism that revealed an effective combination therapy. PLK1 phosphorylated PDCD4 at Ser 239 , leading to its degradation and consequently inducing the transcriptional activation of Hedgehog (Hh) signaling by c-MYC. Hh signaling supports tumor cell proliferation and stemness by inducing the enzyme UDP-glucuronosyltransferase 2B15 (UGT2B15), which promotes the metabolic clearance of drugs and steroid hormones. Thus, this pathway may circumvent androgen receptor dependence, thereby reducing cellular sensitivity to enzalutamide. Knocking down UGT2B15 enhanced enzalutamide-induced cell apoptosis and growth arrest in a PDCD4-dependent manner. Combining enzalutamide with the clinically approved Hh pathway inhibitor vismodegib inhibited cell growth and promoted apoptosis in enzalutamide-resistant cell cultures and xenografts in vivo. Our findings reveal a mechanism of PLK1-mediated enzalutamide resistance and suggest a potential therapeutic strategy to overcome this resistance in prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, KY 40536, USA.
- Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA.
- Gilbert S. Omenn Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI 48109, USA.
ORCID-Profile: Qiongsi Zhang, Jia Peng, Yanquan Zhang, Jinghui Liu, Daheng He, Yifan Kong, Ruixin Wang, Chi Wang, Jianlin Wang, Hsin-Sheng Yang, Xiaoqi Liu
Förderung
- NCI NIH HHS
Zitieren
APA
Zhang, Q., Peng, J., Zhang, Y., Liu, J., He, D., Zhao, Y., Wang, X., Li, C., Kong, Y., Wang, R., Mao, F., Wang, C., Wang, Q., Zhang, M., Wang, J., Yang, H. S., & Liu, X. (2025). The kinase PLK1 promotes Hedgehog signaling–dependent resistance to the antiandrogen enzalutamide in metastatic prostate cancer. Science Signaling, 18(878). https://doi.org/10.1126/scisignal.adi5174
Vancouver
Zhang Q, Peng J, Zhang Y, Liu J, He D, Zhao Y, et al. The kinase PLK1 promotes Hedgehog signaling–dependent resistance to the antiandrogen enzalutamide in metastatic prostate cancer. Science Signaling. 2025;18(878). doi:10.1126/scisignal.adi5174
BibTeX
@article{Zhang2025,
author = {Zhang, Qiongsi and Peng, Jia and Zhang, Yanquan and Liu, Jinghui and He, Daheng and Zhao, Yue and Wang, Xinyi and Li, Chaohao and Kong, Yifan and Wang, Ruixin and Mao, Fengyi and Wang, Chi and Wang, Qing and Zhang, Min and Wang, Jianlin and Yang, Hsin-Sheng and Liu, Xiaoqi},
title = {The kinase PLK1 promotes Hedgehog signaling–dependent resistance to the antiandrogen enzalutamide in metastatic prostate cancer},
journal = {Science Signaling},
year = {2025},
volume = {18},
number = {878},
doi = {10.1126/scisignal.adi5174}
}
EUVIMED